Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010590 · ClinicalTrials.gov registry record · Phase 4
Anabolic Therapy in Postmenopausal Osteoporosis
A Phase 4 study of Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05010590 is a Phase 4 study of Postmenopausal Osteoporosis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 582-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05010590, a Phase 4 study of Postmenopausal Osteoporosis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
Conditions Studied
Interventions
- DRUG Romosozumab
- DRUG Denosumab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010590
The ClinicalTrials.gov registry entry for NCT05010590 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 582-participant average among 12 other Postmenopausal Osteoporosis trials with a reported enrollment target (91% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Romosozumab is the first listed.
NCT05010590 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05010590 about?
NCT05010590 is a clinical study titled "Anabolic Therapy in Postmenopausal Osteoporosis". In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
What is the current status of trial NCT05010590?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2022-03-24. Estimated completion is 2027-11-01.
What conditions does trial NCT05010590 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT05010590?
The interventions under investigation include: Romosozumab (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT05010590?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
COMPLETED · Phase 4
-
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
COMPLETED · Phase 4
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of Monthly Risedronate for Osteoporosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.